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of the study ﬁndings. The aim of this study was to determine whether
there existed signiﬁcant heterogeneity of treatment by center, coun-
try, or baseline risk factors for 5-year MACCE rates in the SYNTAX trial.
METHODS Patient level-data from the 5-year results of the SYNTAX
study were analyzed for the presence of geographical heterogeneity
(site/country) in the effect of treatment (CABG vs PCI) on 5-yr MACCE
rates. Fixed and random effects models examined potential in-
teractions, followed by generalized linear mixed models testing ef-
fects of clinical co-variates, such as diabetes, smoking rates, lesion
characteristics and procedural variations
RESULTS For site-site comparison for 5-yr MACCE rates, the pooled
odds ratio (OR) ¼ 0.58, and for country-country the OR¼0.59. By
simple homogeneity testing, site-stratum differences neared signiﬁ-
cance (73 analyzed sites, X2¼93.8, p¼0.051), whereas no country-
stratum differences (15 countries, X2¼25.7, p¼0.080) were observed.
For random effects models with site or country as the cluster variable,
intra-class correlation was minimal (ICC site ¼ 1.4%, ICC country ¼
0.6%), with no signiﬁcant heterogeneity of treatment effects
observed. Adjusted regression models for age (ICC ¼ 1.6%), male
gender (ICC¼1.2%), had no interaction effect on overall OR for MACCE
(OR¼0.59, 95% CI 0.48, 0.72, p<0.001). Wide variability in incident
baseline risk factors (smoking, diabetes, PVD) was observed - not ac-
counting for signiﬁcant site-site or geographic treatment interaction
in the adjusted models (ICC 1.0%-1.3%). Similarly, we observed wide
ranges across sites for, Left Main disease rates (range 21-57%), TVR
(range 8-31%), and PCI revascularization rates (range 8-31%), even
when pooled by country. Adjusting for Left Main versus 3-vessel
disease in the random effects models suggested PCI was protective of
MACCE (OR¼0.61, p<0.0001), with no difference between LM and 3-
vessel disease (p¼0.185), across site or country strata.
CONCLUSIONS As expected for this RCT, site-site and regional differ-
ences exist. Nonetheless, geographic variability in standard risk,
responsiveness to treatment, and vulnerability to adverse outcomes,
assessed by current models for heterogeneity analysis in clinical trials,
shows no signiﬁcant treatment effect. These ﬁndings highlight the
utility andgeneralizability of the 5-year outcomes of the SYNTAX study.
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BACKGROUND The incidence of peri-procedural myocardial infarc-
tion (PPMI) in patients treated with percutaneous coronary inter-
vention (PCI) varies largely between studies, and its clinical relevance
still remains a matter of debate. We sought to examine the incidence
of PPMI after bifurcation PCI using different deﬁnitions from the
TRYTON randomized trial.
METHODS The TRYTON trial randomized 704 patients with bifurcation
undergoing PCI to the Tryton side branch (SB) stentwithmain branch (MB)
DES vs. provisional SB treatment with MB DES. In the current study, we
reported and compared the incidence of PPMI after PCI, deﬁned according
three different deﬁnitions: per protocol (CK-MB 3 ULN), 3rd universal
(troponin rise of > 5  ULN), and SCAI (CK-MB rise of 10  ULN).RESULTS PPMI occurred in 81 out of 704 patients (11.5%) according to
the protocol deﬁnition, in 137 patients (19.5%), according to the
troponin-based third universal deﬁnition, and in 1.0% according to the
SCAI deﬁnition, with no signiﬁcant difference between the Tryton and
provisional group (Table). Access site (femoral vs radial; OR 0.60, 95%
CI 0.37-0.98), main vessel lesion length (OR 1.04, 95% CI 1.00-1.07),
and main vessel diameter stenosis (OR 1.02, 95% CI 1.00-1.05), the use
of devices other than angioplasty balloon (OR 3.77, 95% CI 1.02-13.86),
and the use of “non-study” stents were identiﬁed as independent
predictors of per-protocol PPMI. At 12-month follow-up, there were no
cardiac death in PPMI and two (5.9%) in no-PPMI patients (p¼0.61).
Patients who experienced protocol-deﬁned PPMI had signiﬁcantly
more target vessel revascularizations (11.1% vs. 5.1%; p¼0.02).Deﬁnition used Tryton Provisional Combined p-valueProtocol: CK-MB rise of
> 3x ULN13.6% (47/345) 10.1% (34/336) 11.5% (81/704) 0.193rd universal: troponin rise
of > 5  ULN
20.0% (71/355) 18.9% (66/349) 19.5% (137/704) 0.72SCAI: CK-MB rise of
10  ULN
1.4% (5/355) 0.6% (2/349) 1.0% (7/704) 0.26CONCLUSIONS The incidence of PPMI varies signiﬁcantly (by tenfold)
according to the deﬁnition used. However, PPMI, independent of the
PPMI deﬁnition, was not associated with an increase in cardiac mor-
tality at 1-year follow-up. These ﬁndings are important and may have
important implications when designing and selecting components of a
primary composite endpoint for PCI randomized trial.
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BACKGROUND Previous studies have shown that deferral of revas-
cularization in lesions with a fractional ﬂow reserve (FFR) > 0.80 is
safe and associated with signiﬁcantly lower incidence of major
adverse cardiovascular events (MACE) as compared to angiographic-
ally guided revascularization. DM patients have an accelerated
atherosclerosis progression compared to patients without DM.
Whether FFR-guided revascularization is also valid in DM patients is
unknown, therefore we performed a retrospective study in our center.
METHODS We assessed all consecutive DMpatients that underwent FFR-
guided revascularization between January 2011 and December 2013, and
followed them until May 2015. We further divided these patients into two
groups according to the presence or absence of 1 FFR-negative lesion (
0.80) remaining after index revascularization. DM was deﬁned as self-re-
ported by treatment with anti-diabetic medication or diet. The primary
endpoint was the incidence of MACE deﬁned as a composite of death,
myocardial infarction (MI), target lesion revascularization (TLR) or reho-
spitalization for acute coronary syndrome (ACS). Target lesionwas deﬁned
as the lesion(s) in which the FFR was performed. Logistic regression
analysis was performed to assess for predictors of MACE.
RESULTS Of the 224 DM patients that underwent FFR-guided revas-
cularization, 152(67.9%) had 1 FFR-negative lesion (Defer Group, DG)
while 72(32.1%) had only FFR-positive lesions, with resultant index
revascularization (Revascularization Group, RG). Overall, baseline
characteristics were well matched between groups, however there
were more females (37.5% vs 23.6%, p¼0.04) in the DG, while rates of
smoking (19.7% vs 34.7%, p¼0.02) and prior PCI (41.4% vs 56.9%,
p¼0.03) were higher in the RG. The MACE rate was 34.2% in the DG
and 26.4% in the RG, p¼ 0.24. The incidence of death was similar in
both groups 15.8% vs 15.3% p¼0.92. However a signiﬁcantly higher
rate of TLR (13.2% vs 4.2%, p¼0.038) and rehospitalization for ACS
(33.6% vs 19.4%, p¼0.03) was observed in the DG group. Similarly a
numerically higher incidence of MI was also observed but did not
reach signiﬁcance (7.2% vs 4.2%, p¼0.56). Logistic regression analysis
showed that increasing age, elevated HbA1c and renal insufﬁciency
B202 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5were predictors of MACE. The presence of a lesion with a negative FFR
was not a statistically signiﬁcant predictor for MACE (OR 1.65, 95% CI
0.78-3.50, p¼0.2) after adjustment for confounders.
CONCLUSIONS This study, the ﬁrst to examine an FFR guided strategy in
DMpatients, shows similar MACE rates in both groups, however the event
rateswere numerically higher in the DG. The differencewasmainly driven
by a signiﬁcantly higher rate of TLR and re-hospitalization for ACS, and a
numericallyhigher rateofMI.Due to its limitedpower, this studyshouldbe
considered as hypothesis generating, however it raises the question if an
FFR-guided revascularization strategy is safe in patients with fast pro-
gressing plaque as in DM patients.
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BACKGROUND The management of coronary in-stent restenosis (ISR)
is challenging and the most effective interventional treatment is still
undeﬁned. We aimed to compare different interventional strategies
for coronary ISR to assess the relative efﬁcacy in reducing target lesion
revascularization (TLR).
METHODS Randomized trials comparing two different treatmentswere
searched in PubMed, Embase, Scopus, Cochrane Library, Web of Science,
and ScienceDirect electronic databases and major scientiﬁc websites. The
searchwasperformed fromthedateofdatabases inception to 30December
2014. Patients of any age, gender, ischemic risk proﬁle, and clinical pre-
sentation were included and any type of ISR, both bare-metal stent(BMS)-
ISR and drug-eluting stent (DES)-ISR, both ﬁrst ISR and recurrent ISR, was
considered. Trials comparing non-interventional treatments, variants of
the same typeof device,multiple strategies for ISR in the samegroupat the
same timewere excluded. The endpointwas TLR, deﬁned as any repeated
revascularization involving the target lesion, both percutaneous and sur-
gical, at 6-12 months. Data used in this meta-analysis were intention-to-
treat. A hierarchical Bayesian networkmeta-analysiswas carried out using
a random effects consistency model computed by Markov Chain Monte
Carlo methods with Gibbs sampling based on 100,000 iterations following
discard of 50,000 “burn-in” iterations. Posterior inference was expressed
as odds ratio (OR) and 95% credibility interval (CrI). Heterogeneity was
graded using I2 statistic. Inconsistency was explored using network
“node-split”.
RESULTS A total of 24 trials (4,880 patients) and 7 interventional
treatments (Plain Balloon [PB], drug-coated balloon [DCB], DES, BMS,
brachytherapy [BT], rotational atherectomy [ROTA], and cutting
balloon [CUT]) were included in this meta-analysis. DCB and DES were
associated with a signiﬁcant reduction in the risk of TLR compared
with all the other treatments. PB anti-restenotic effect was comparable
with those of BMS, BT, ROTA, and CUT. No difference in TLR between
DCB and DES was observed (DCB vs. DES: OR 1.11, 95% CrI 0.59-2.07).
CONCLUSIONS DCB and DES are the most effective interventional
strategies for ISR and PB alone should no longer be considered. BMS,
BT, ROTA and CUT present anti-restenotic effects similar to PB.
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BACKGROUND Patients presenting with recurrent angina after a
remote history of coronary artery bypass grafting (CABG) represent a
challenge in adequately resolving symptoms due to native disease
progression, and graft attrition. While the favored treatment modal-
ities consist mainly of medical therapy or percutaneous coronary
intervention (PCI), there is limited data available on the subsequent
clinical outcomes. We therefore report the long term outcomes of
patients with a history of CABG who underwent repeat angiography
for recurrence of stable angina.
METHODS We retrospectively collected clinical data on patients with a
history of prior CABG who underwent angiography after presenting with
angina between Jan 2008 and Dec 2012. Treatment allocation was at the
physician’s discretion at the time of angiography. Data was collected from
the hospital angiography database, outpatient review and welsh de-
mographic service. Patients presenting with an ACS were excluded.
RESULTS 287 consecutive patients (mean age 67.6 yrs, 88% male) un-
derwent coronary angiography after presenting with angina. 173 patients
were treatedmedically, 114 patients treated with PCI. Patients assigned to
medical therapy had lower mean CCS angina class compared to the PCI
cohort (2.16 vs 2.50 p<0.001). Both groups were well matched for baseline
demographics. In the PCI group, native vessels were treated in 78.9% of
cases and vein grafts in 21%. Following treatment, angina status decreased
signiﬁcantly in both groups (0.96 formedically treated and 1.33 for the PCI
group, p<0.001 for both, P¼ns between groups). Mean NYHA class also
decreased signiﬁcantly in both groups (by 1.06 for the medically treated
group and 1.1 for the PCI group p<0.001 for both groups P ¼ns between
groups). In the PCI group signiﬁcant improvement in anginawas greater in
the native vessel group compared to the graft PCI groups (1.27vs1.07
p<0.05). Therewas higherMACE rates at 1 year in themedical group 21.4%
vs 7.0% in the PCI group (p<0.001). This was driven mainly by MI and
rehospitalization for cardiac causes (18.5% and 25.4% respectively in the
medical group compared to 5.3%, 12.3% for the PCI group). Over a mean
followupperiodof 3 years, therewasnodifference in all-causemortality in
either cohort (Medical 7.5%vsPCI 4.3% p¼0.18). One year mortality was
higher in vein graft PCI group than native vessels (0% vs 8%, P<0.05).
CONCLUSIONS In patients presenting with recurrent angina after previ-
ous CABG, patients treated with PCI had higher angina burden than those
treated medically. Equivalent symptomatic improvements was achieved
with PCI andmedical therapy. Therewas signiﬁcantly lessMACE in the PCI
group compared to medical therapy with a trend to mortality beneﬁt at
3yrs. Native vessel PCI had better 1yr outcomes than SVG-PCI in these
subgroups. Once patients represent with angina post CABG, continuing
symptom burden and recurrent clinical events remains problematic and
further treatments are required to optimize outcomes.
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BACKGROUND Drug-eluting stent (DES) and drug-coated balloon
(DCB) seem to be the most effective treatments for coronary in-stent
restenosis (ISR). We performed a meta-analysis of randomized trials
comparing DES and DCB for ISR in the attempt to deﬁne whether one
of these treatments presents a higher anti-restenotic efﬁcacy.
METHODS Randomized trials comparing DES and DCB for ISR were
searched inPubMed,Embase,Scopus,CochraneLibrary,WebofScience,and
ScienceDirect electronic databases. No clinical or angiographic restrictions
were imposed. The endpoint was target lesion revascularization (TLR) at 12
months, deﬁned as any repeated revascularization involving the target
lesion, both percutaneous and surgical. Data used in thismeta-analysis were
